Testing effectiveness (Phase 2)Looking for participantsNCT06818058What this trial is testingTAR-0520 Gel in EGFR Inhibitor-induced FolliculitisWho this might be right forEGFR Inhibitor-associated Rash Tarian Pharma 60
Not applicableWithdrawnNCT01349556What this trial is testingPrevention of Drug Rash From Certain Cancer Therapies Using Tretinoin CreamWho this might be right forMedication Reaction Johns Hopkins University
Testing effectiveness (Phase 2)Study completedNCT04239846What this trial is testingProphylactic Treatment of Skin Rash Associated With EGFR Inhibitor TherapyWho this might be right forEGFR Inhibitor-Induced Skin Rash TWi Biotechnology, Inc. 74
Not applicableUnknownNCT00498992What this trial is testingRegenecare® Wound Gel in Treating Rash in Patients Receiving Cetuximab or Other Epidermal Growth Factor Receptor Inhibitor Therapy for CancerWho this might be right forDermatologic ComplicationsUnspecified Adult Solid Tumor, Protocol Specific Ingalls Memorial Hospital 20
Testing effectiveness (Phase 2)UnknownNCT04759664What this trial is testingLUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRCWho this might be right forEGFRI Induced Acneiform Lesions Lutris Pharma Ltd. 117
Testing effectiveness (Phase 2)Looking for participantsNCT05639933What this trial is testingStudy to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor InhibitorsWho this might be right forAcneiform Eruption Due to ChemicalXerosis CutisParonychia Hoth Therapeutics, Inc. 152
Early research (Phase 1)Study completedNCT00656786What this trial is testingSafety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated RashWho this might be right forEGFR Inhibitor-associated Rash Spectrum Pharmaceuticals, Inc 18
Testing effectiveness (Phase 2)Looking for participantsNCT06830863What this trial is testingEvaluate Topical ATR04-484 for EGFRi-Associated Dermal ToxicityWho this might be right forEGFR Inhibitor-associated Rash Azitra Inc. 32